JP7505680B2 - Composition for enhancing filaggrin and/or involucrin gene expression, and composition for stimulating fibroblasts - Google Patents
Composition for enhancing filaggrin and/or involucrin gene expression, and composition for stimulating fibroblasts Download PDFInfo
- Publication number
- JP7505680B2 JP7505680B2 JP2020118002A JP2020118002A JP7505680B2 JP 7505680 B2 JP7505680 B2 JP 7505680B2 JP 2020118002 A JP2020118002 A JP 2020118002A JP 2020118002 A JP2020118002 A JP 2020118002A JP 7505680 B2 JP7505680 B2 JP 7505680B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- filaggrin
- dehydrozingerone
- composition according
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 71
- 210000002950 fibroblast Anatomy 0.000 title claims description 37
- 108010033564 involucrin Proteins 0.000 title claims description 35
- 102000007236 involucrin Human genes 0.000 title claims description 33
- 230000014509 gene expression Effects 0.000 title claims description 29
- 230000002708 enhancing effect Effects 0.000 title claims description 14
- 102100028314 Filaggrin Human genes 0.000 title description 37
- 101710088660 Filaggrin Proteins 0.000 title description 37
- 230000004936 stimulating effect Effects 0.000 title description 7
- AFWKBSMFXWNGRE-ONEGZZNKSA-N Dehydrozingerone Chemical compound COC1=CC(\C=C\C(C)=O)=CC=C1O AFWKBSMFXWNGRE-ONEGZZNKSA-N 0.000 claims description 45
- AFWKBSMFXWNGRE-UHFFFAOYSA-N dehydrozingerone Natural products COC1=CC(C=CC(C)=O)=CC=C1O AFWKBSMFXWNGRE-UHFFFAOYSA-N 0.000 claims description 45
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- -1 antifungal Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 8
- 244000008991 Curcuma longa Species 0.000 description 7
- 108700041153 Filaggrin Proteins Proteins 0.000 description 7
- 241000234299 Zingiberaceae Species 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 235000003373 curcuma longa Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 235000014375 Curcuma Nutrition 0.000 description 5
- 244000163122 Curcuma domestica Species 0.000 description 5
- 235000003392 Curcuma domestica Nutrition 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 235000013976 turmeric Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 244000273928 Zingiber officinale Species 0.000 description 4
- 235000006886 Zingiber officinale Nutrition 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000008397 ginger Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000234314 Zingiber Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004296 ribosomal protein S18 Human genes 0.000 description 3
- 108090000842 ribosomal protein S18 Proteins 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000976051 Homo sapiens Involucrin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000003398 Curcuma aromatica Nutrition 0.000 description 1
- 240000005629 Curcuma phaeocaulis Species 0.000 description 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 244000164418 Curcuma xanthorrhiza Species 0.000 description 1
- 235000003393 Curcuma xanthorrhiza Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000917159 Homo sapiens Filaggrin Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Description
本発明は、フィラグリン及び／又はインボルクリン遺伝子発現増強用組成物、並びに、線維芽細胞賦活用組成物に関する。 The present invention relates to a composition for enhancing filaggrin and/or involucrin gene expression, and a composition for stimulating fibroblasts.
皮膚は表皮と真皮とから構成される。表皮の機能の一つは体内から水分が逃げないようにする水分保持機能である。一方、真皮は、細胞が少なく、細胞外マトリックスと水とを主成分とする。細胞外マトリックスは、コラーゲン線維、エラスチン線維等の皮膚の張りや弾力性に関わるタンパク質線維や、保水性の維持に重要なプロテオグリカン（ヒアルロン酸、デルマタン硫酸、コンドロイチン硫酸等）の基質により構成される。真皮に含まれる細胞の１つが線維芽細胞であり、線維芽細胞は細胞外マトリックス成分を合成しており、線維芽細胞の活動状態が細胞の張りや弾力性に重要な影響を及ぼす。線維芽細胞の活性が増強されると、皮膚の状態が改善することが知られている。フィラグリン及びインボルクリンは皮膚の保湿やバリア機能に関連する因子として知られている。 The skin is composed of the epidermis and dermis. One of the functions of the epidermis is to retain moisture so that moisture does not escape from the body. On the other hand, the dermis has fewer cells and is mainly composed of extracellular matrix and water. The extracellular matrix is composed of protein fibers such as collagen fibers and elastin fibers that are involved in the firmness and elasticity of the skin, and a substrate of proteoglycans (hyaluronic acid, dermatan sulfate, chondroitin sulfate, etc.) that are important in maintaining water retention. One of the cells contained in the dermis is the fibroblast, which synthesizes extracellular matrix components, and the activity state of fibroblasts has an important effect on the firmness and elasticity of the cells. It is known that skin condition improves when fibroblast activity is enhanced. Filaggrin and involucrin are known as factors related to skin moisturization and barrier function.
特許文献１には、ビサクロンを含むウコン水抽出物を経口摂取することにより、紫外線照射後の皮膚水分が保持され保湿効果が達成されることが記載されている。
特許文献２には、ショウガ科ウコン属植物の抽出物が、優れた真皮線維芽細胞賦活活性を有することが記載されている。
非特許文献１には、ウコン熱水抽出物が、ＵＶ照射により誘導されるＴＮＦα及びインターロイキン１βの増加を抑制し、抗炎症作用を示すこと、角化細胞によるヒアルロン酸産生を促進すること、皮膚の保湿作用を有することが記載されている。
Non-Patent
非特許文献２には、ウコン抽出物を適用した真皮創傷部位においてＴＧＦ－β１が有意に増加し、線維芽細胞でフィブロネクチンやコラーゲンの生成が行われ、肉芽組織の形成つまり創傷治癒の促進が観察されたことが記載されている。
Non-patent
一方、ウコンやショウガに含まれる生理活性成分のデヒドロジンゲロンは抗酸化、抗癌、抗炎症、抗うつ、抗マラリア、抗真菌、抗血小板等の作用が知られている。 On the other hand, dehydrozingerone, a physiologically active ingredient found in turmeric and ginger, is known to have antioxidant, anticancer, anti-inflammatory, antidepressant, antimalarial, antifungal, and antiplatelet properties.
シワ形成、肌荒れ、乾燥肌等の皮膚のトラブルを改善するためには、皮膚保湿やバリア機能に関与する因子であるフィラグリン又はインボルクリンの産生を促進させることや、線維芽細胞を賦活することが有効であると考えられる。 In order to improve skin problems such as wrinkle formation, rough skin, and dry skin, it is believed that promoting the production of filaggrin or involucrin, which are factors involved in skin moisturization and barrier function, and activating fibroblasts are effective.
そこで本発明は、食品として摂取可能な物質を有効成分として含む、フィラグリン及び／又はインボルクリン遺伝子発現増強用組成物、並びに、線維芽細胞賦活用組成物を提供する。 The present invention provides a composition for enhancing the expression of filaggrin and/or involucrin genes, and a composition for stimulating fibroblasts, which contains a substance that can be ingested as a food as an active ingredient.
本発明者らは、ウコンやショウガに含まれる成分であるデヒドロジンゲロンが、フィラグリン及び／又はインボルクリンの遺伝子発現を増強する作用、及び、線維芽細胞を賦活する作用を有することを見出し、以下の本発明を完成するに至った。
（１）デヒドロジンゲロンを有効成分として含有する、フィラグリン及び／又はインボルクリン遺伝子発現増強用組成物。
（２）デヒドロジンゲロンを有効成分として含有する、線維芽細胞賦活用組成物。
The present inventors have discovered that dehydrozingerone, a component contained in turmeric and ginger, has the effect of enhancing gene expression of filaggrin and/or involucrin, and of activating fibroblasts, and have thus completed the present invention.
(1) A composition for enhancing filaggrin and/or involucrin gene expression, comprising dehydrozingerone as an active ingredient.
(2) A composition for stimulating fibroblasts, comprising dehydrozingerone as an active ingredient.
本発明によれば、食品として摂取可能な物質であるデヒドロジンゲロンを有効成分として含む、フィラグリン及び／又はインボルクリン遺伝子発現増強用組成物、並びに、線維芽細胞賦活用組成物が提供される。 The present invention provides a composition for enhancing the expression of filaggrin and/or involucrin genes, and a composition for stimulating fibroblasts, which contain dehydrozingerone, a substance that can be ingested as a food, as an active ingredient.
＜デヒドロジンゲロン＞
デヒドロジンゲロンは、下記の式：
Dehydrozingerone has the following formula:
デヒドロジンゲロンは植物に由来するものであってもよいし、人為的に合成されたものであってもよい。 Dehydrozingerone may be derived from plants or may be synthetically produced.
前記植物としてはショウガ科ウコン属植物、ショウガ科ショウガ属植物等が例示できる。ショウガ科ウコン属植物としては、具体的には、Ｃｕｒｃｕｍａ ｌｏｎｇａ（秋ウコン）、Ｃｕｒｃｕｍａ ａｒｏｍａｔｉｃａ、Ｃｕｒｃｕｍａ ｚｅｄｏａｒｉａ、Ｃｕｒｃｕｍａ ｐｈａｅｏｃａｕｌｉｓ、Ｃｕｒｃｕｍａ ｋｗａｎｇｓｉｎｅｎｓｉｓ、Ｃｕｒｃｕｍａ ｗｅｎｙｕｊｉｎ、及び／又は、Ｃｕｒｃｕｍａ ｘａｎｔｈｏｒｒｈｉｚａが挙げられる。ショウガ科ショウガ属植物としては、具体的にはＺｉｎｇｉｂｅｒ ｏｆｆｉｃｉｎａｌｅ（ショウガ）が挙げられる。
デヒドロジンゲロンはショウガ科ウコン属植物又はショウガ科ショウガ属植物の根茎に由来するものであってよい。
デヒドロジンゲロンは、植物の破砕物、搾汁、抽出物又はそれらの処理物等に含まれる形態であってもよい。
Examples of the plant include plants of the genus Curcuma of the Zingiberaceae family and plants of the genus Zingiber of the Zingiberaceae family. Specific examples of plants of the genus Curcuma of the Zingiberaceae family include Curcuma longa (autumn turmeric), Curcuma aromatica, Curcuma zedoaria, Curcuma phaeocaulis, Curcuma kwangsinensis, Curcuma wenyujin, and/or Curcuma xanthorrhiza. Specific examples of plants of the genus Zingiber of the Zingiberaceae family include Zingiber officinale (ginger).
Dehydrozingerone may be derived from the rhizome of a plant of the genus Curcuma of the Zingiberaceae family or the rhizome of a plant of the genus Zingiber of the Zingiberaceae family.
Dehydrozingerone may be in a form contained in crushed material, juice, extract, or processed products thereof from the plant.
デヒドロジンゲロンは、植物、或いは、植物の破砕物、搾汁、抽出物又はそれらの処理物から分離された形態であってもよいし、分離され精製された形態であってもよい。
デヒドロジンゲロンは、人為的に合成され、精製されたものであってもよい。
Dehydrozingerone may be in a form isolated from the plant, or from crushed material, juice, extract, or processed material of the plant, or may be in an isolated and purified form.
Dehydrozingerone may be artificially synthesized and purified.
＜フィラグリン及び／又はインボルクリン遺伝子発現増強用組成物＞
本発明の第一の実施形態は、デヒドロジンゲロンを有効成分として含有する、フィラグリン及び／又はインボルクリン遺伝子発現増強用組成物に関する。
本発明の第一の実施形態に係る組成物の対象は典型的にはヒトであるが、ヒトには限定されず他の非ヒト動物、例えばヒト以外の哺乳類であってもよい。
<Composition for enhancing filaggrin and/or involucrin gene expression>
A first embodiment of the present invention relates to a composition for enhancing filaggrin and/or involucrin gene expression, which contains dehydrozingerone as an active ingredient.
The subject of the composition according to the first embodiment of the present invention is typically a human, but is not limited to a human and may be other non-human animals, for example, mammals other than humans.
フィラグリン及びインボルクリンは、皮膚の保湿やバリア機能に関連する因子である。フィラグリン及び／又はインボルクリンの遺伝子発現の増強により、皮膚の保湿や、シワ形成、肌荒れ、乾燥肌等の皮膚のトラブルの予防又は改善が達成される。 Filaggrin and involucrin are factors related to skin moisturization and barrier function. Increasing gene expression of filaggrin and/or involucrin can help moisturize the skin and prevent or improve skin problems such as wrinkle formation, rough skin, and dry skin.
フィラグリンはポリタンパク質前駆体であるプロフィラグリンとして発現する。プロフィラグリンがタンパク質分解による加工を受けて、機能を有する複数のフィラグリン分子が生じる。このため、フィラグリンの遺伝子発現の増強は、プロフィラグリンの遺伝子発現の増強と言い換えてもよい。本明細書では特に限定しない限り、フィラグリンとは、前駆体であるプロフィラグリンと成熟したフィラグリンのどちらであってもよい Filaggrin is expressed as a polyprotein precursor, profilaggrin, which is proteolytically processed to produce multiple functional filaggrin molecules. Therefore, enhancing gene expression of filaggrin can be rephrased as enhancing gene expression of profilaggrin. Unless otherwise specified in this specification, filaggrin may be either the precursor profilaggrin or mature filaggrin.
フィラグリン及び／又はインボルクリンの遺伝子発現が増強されていることは、本発明の第一の実施形態に係る組成物を摂取又は投与した対象から採取した細胞（好ましくは表皮角化細胞）、或いは、本発明の第一の実施形態に係る組成物の存在下で培養した細胞（好ましくは表皮角化細胞）中のｍＲＮＡからｃＤＮＡを調製し、該ｃＤＮＡを鋳型とし、プロフィラグリンのｃＤＮＡ塩基配列（５’非翻訳領域、コーディング領域及び／又は３’非翻訳領域、好ましくはコーディング領域）、及び／又は、インボルクリンのｃＤＮＡ塩基配列（５’非翻訳領域、コーディング領域及び／又は３’非翻訳領域、好ましくはコーディング領域）の少なくとも一部を特異的に増幅し得るプライマーセットを用いた核酸増幅反応を行い、該反応による増幅産物量を検出することで確認することができる。プロフィラグリンのｃＤＮＡ塩基配列を増幅するためのプライマーセットとしては、配列番号１に示す塩基配列を含むプライマーと、配列番号２に示す塩基配列を含むプライマーとのセットが例示できる。インボルクリンのｃＤＮＡ塩基配列を増幅し得るプライマーセットとしては、配列番号３に示す塩基配列を含むプライマーと、配列番号４に示す塩基配列を含むプライマーとのセットが例示できる。 The enhanced gene expression of filaggrin and/or involucrin can be confirmed by preparing cDNA from mRNA in cells (preferably epidermal keratinocytes) collected from a subject who has ingested or administered the composition according to the first embodiment of the present invention, or in cells (preferably epidermal keratinocytes) cultured in the presence of the composition according to the first embodiment of the present invention, and using the cDNA as a template, carrying out a nucleic acid amplification reaction using a primer set capable of specifically amplifying at least a portion of the cDNA base sequence of profilaggrin (5' untranslated region, coding region and/or 3' untranslated region, preferably coding region) and/or the cDNA base sequence of involucrin (5' untranslated region, coding region and/or 3' untranslated region, preferably coding region), and detecting the amount of the amplified product by the reaction. An example of a primer set for amplifying the cDNA base sequence of profilaggrin is a set of a primer containing the base sequence shown in SEQ ID NO: 1 and a primer containing the base sequence shown in SEQ ID NO: 2. An example of a primer set capable of amplifying the cDNA base sequence of involucrin is a set of a primer containing the base sequence shown in SEQ ID NO: 3 and a primer containing the base sequence shown in SEQ ID NO: 4.
また、フィラグリン及び／又はインボルクリンの遺伝子発現が増強されていることは、本発明の第一の実施形態に係る組成物を摂取又は投与した対象から採取した細胞（好ましくは表皮角化細胞）、或いは、本発明の第一の実施形態に係る組成物の存在下で培養した細胞（好ましくは表皮角化細胞）において、フィラグリン及び／又はインボルクリンのタンパク質の量を検出することで確認することができる。細胞中でフィラグリン及び／又はインボルクリンのタンパク質の量が増加している場合に、フィラグリン及び／又はインボルクリンの遺伝子発現が増強されていると評価することができる。 Furthermore, enhanced gene expression of filaggrin and/or involucrin can be confirmed by detecting the amount of filaggrin and/or involucrin protein in cells (preferably epidermal keratinocytes) collected from a subject who has ingested or been administered the composition according to the first embodiment of the present invention, or in cells (preferably epidermal keratinocytes) cultured in the presence of the composition according to the first embodiment of the present invention. When the amount of filaggrin and/or involucrin protein in the cells is increased, it can be evaluated that gene expression of filaggrin and/or involucrin is enhanced.
ヒト由来フィラグリンのポリタンパク質前駆体であるヒト由来プロフィラグリンのｃＤＮＡ塩基配列を配列番号７に示す。配列番号７の塩基配列のうち第７３位～第１２２５５位がコーディング領域である。このコーディング領域がコードするヒト由来プロフィラグリンのアミノ酸配列を配列番号８に示す。
ヒト由来インボルクリンのｃＤＮＡ塩基配列を配列番号９に示す。配列番号９の塩基配列のうち第６５位～第１８１９位がコーディング領域である。このコーディング領域がコードするヒト由来インボルクリンのアミノ酸配列を配列番号１０に示す。
The cDNA base sequence of human profilaggrin, which is a polyprotein precursor of human filaggrin, is shown in SEQ ID NO: 7. In the base sequence of SEQ ID NO: 7, the coding region is from positions 73 to 12255. The amino acid sequence of human profilaggrin encoded by this coding region is shown in SEQ ID NO: 8.
The cDNA base sequence of human involucrin is shown in SEQ ID NO: 9. In the base sequence of SEQ ID NO: 9, the coding region is from positions 65 to 1819. The amino acid sequence of human involucrin encoded by this coding region is shown in SEQ ID NO: 10.
本発明の第一の実施形態に係る組成物の対象は、好ましくは、フィラグリン及び／又はインボルクリンの遺伝子発現の増強を必要とする或いは望む対象である。また、本発明の第一の実施形態に係る組成物は、健常な対象に対しても有効である。 The subject of the composition according to the first embodiment of the present invention is preferably a subject who requires or desires enhanced gene expression of filaggrin and/or involucrin. The composition according to the first embodiment of the present invention is also effective for healthy subjects.
本発明の第一の実施形態に係る組成物は、医薬品、飲食品、化粧品等の各形態の組成物であってよい。飲食品は、機能性表示食品、特定保健用食品、栄養補給のためのサプリメント等の形態のものも包含する。 The composition according to the first embodiment of the present invention may be in the form of a pharmaceutical, food or drink, cosmetic, etc. Food or drink also includes those in the form of functional food, food for specified health use, nutritional supplement, etc.
本発明の第一の実施形態に係る組成物は、好ましくは、経口又は経鼻により摂取又は投与される組成物であり、より好ましくは、経口により摂取又は投与される組成物である。
本発明の第一の実施形態に係る組成物はまた、皮膚に適用され経皮投与される組成物であってもよい。
The composition according to the first embodiment of the present invention is preferably a composition that is ingested or administered orally or nasally, and more preferably a composition that is ingested or administered orally.
The composition according to the first embodiment of the present invention may also be a composition that is applied to the skin and administered transdermally.
本発明の第一の実施形態に係る組成物はまた、生体外の細胞と共存させることにより該細胞においてフィラグリン及び／又はインボルクリンの遺伝子発現を増強するための組成物であってもよい。この場合、本発明の第一の実施形態に係る組成物は、細胞を培養するための培地中に添加されて使用される。 The composition according to the first embodiment of the present invention may also be a composition for enhancing gene expression of filaggrin and/or involucrin in cells ex vivo by coexisting with the cells. In this case, the composition according to the first embodiment of the present invention is used by adding it to a medium for culturing the cells.
本明細書において「１日の使用量」とは、本発明の第一の実施形態又は後述する第二の実施形態に係る組成物の、一日間で摂取、投与又は使用される量の総量を意味し、好ましくは、ヒト一人、特に成人一人により、本発明の第一の実施形態又は第二の実施形態に係る組成物が一日間で摂取、投与又は使用される量の総量を意味する。「１日の使用量」の具体例として、本発明の第一の実施形態又は第二の実施形態に係る組成物の量として０．１ｇ～５００ｇが例示できる。
本発明の第一の実施形態に係る組成物は、継続的に摂取、投与又は使用されてもよいし、必要時に摂取、投与又は使用されてもよい。
In this specification, the term "amount used per day" refers to the total amount of the composition according to the first embodiment of the present invention or the composition according to the second embodiment described later that is ingested, administered or used in one day, and preferably refers to the total amount of the composition according to the first embodiment or the second embodiment of the present invention that is ingested, administered or used in one day by one human, particularly one adult. A specific example of the "amount used per day" is 0.1 g to 500 g of the composition according to the first embodiment or the second embodiment of the present invention.
The composition according to the first embodiment of the present invention may be ingested, administered or used continuously, or may be ingested, administered or used when needed.
本発明の第一の実施形態に係る組成物におけるデヒドロジンゲロンの含有量は特に限定されず、例えば、組成物全量あたり０．１～９５重量％のデヒドロジンゲロンを含むことができ、或いは、１日の使用量あたり１μｇ～１０ｇのデヒドロジンゲロンを含むことができる。 The content of dehydrozingerone in the composition according to the first embodiment of the present invention is not particularly limited, and may be, for example, 0.1 to 95% by weight of dehydrozingerone per total amount of the composition, or 1 μg to 10 g of dehydrozingerone per daily usage amount.
本発明の第一の実施形態に係る組成物の形状は、特に限定されず、例えば、液体状、流動状、ゲル状、半固形状、又は固形状などの何れの形状であってもよい。 The shape of the composition according to the first embodiment of the present invention is not particularly limited, and may be, for example, any of liquid, fluid, gel, semi-solid, or solid forms.
本発明の第一の実施形態に係る組成物は、デヒドロジンゲロンに加えて、少なくとも１種の他の成分を更に含んでいてもよい。本発明の第一の実施形態に係る組成物が含み得る、少なくとも１種の他の成分としては、特に限定されないが、好ましくは、医薬品、飲食品、化粧品等の最終的な形態において許容される成分である。 The composition according to the first embodiment of the present invention may further contain at least one other component in addition to dehydrozingerone. The at least one other component that may be contained in the composition according to the first embodiment of the present invention is not particularly limited, but is preferably an ingredient that is acceptable in the final form of a drug, food or beverage, cosmetic, etc.
このような他の成分としては例えば、甘味料、酸味料、ビタミン類、ミネラル類、増粘剤、乳化剤、酸化防止剤、水等が挙げられる。また、必要により、色素、香料、保存料、防腐剤、防かび剤、更なる生理活性物質等を添加してもよい。 Examples of such other ingredients include sweeteners, acidulants, vitamins, minerals, thickeners, emulsifiers, antioxidants, water, etc. Furthermore, colorants, flavors, preservatives, antiseptics, fungicides, and other biologically active substances may be added as necessary.
甘味料としては、ブドウ糖、果糖、ショ糖、乳糖、麦芽糖、パラチノース、トレハロース、キシロース等の単糖や二糖、異性化糖（ブドウ糖果糖液糖、果糖ブドウ糖液糖、砂糖混合異性化糖等）、糖アルコール（エリスリトール、キシリトール、ラクチトール、パラチニット、ソルビトール、還元水飴等）、はちみつ、高甘味度甘味料（スクラロース、アセスルファムカリウム、ソーマチン、ステビア、アスパルテーム等）等が挙げられる。 Sweeteners include monosaccharides and disaccharides such as glucose, fructose, sucrose, lactose, maltose, palatinose, trehalose, and xylose, isomerized sugars (glucose-fructose liquid sugar, fructose-glucose liquid sugar, mixed sugar isomerized sugar, etc.), sugar alcohols (erythritol, xylitol, lactitol, palatinit, sorbitol, reduced starch syrup, etc.), honey, and high-intensity sweeteners (sucralose, acesulfame potassium, thaumatin, stevia, aspartame, etc.).
酸味料としては、クエン酸、リンゴ酸、グルコン酸、酒石酸、乳酸、リン酸、又はこれらの塩等があり、これらのうちの１種又は２種以上を利用することができる。
ビタミン類としては、ビタミンＡ、ビタミンＢ１、ビタミンＢ２、ビタミンＢ６、ビタミンＥ、ナイアシン、イノシトール等が挙げられる。
ミネラル類としては、カルシウム、マグネシウム、亜鉛、鉄等が挙げられる。
The acidulant may be citric acid, malic acid, gluconic acid, tartaric acid, lactic acid, phosphoric acid, or salts thereof, and one or more of these may be used.
Examples of vitamins include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin E, niacin, and inositol.
Examples of minerals include calcium, magnesium, zinc, and iron.
増粘剤としては、カラギーナン、ジェランガム、キサンタンガム、アラビアガム、タマリンドガム、グアーガム、ローカストビーンガム、カラヤガム、寒天、ゼラチン、ペクチン、大豆多糖類、カルボキシメチルセルロース（ＣＭＣ）等が挙げられる。
乳化剤としては、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステル、レシチン、植物性ステロール、サポニン等が挙げられる。
酸化防止剤としては、ビタミンＣ、トコフェロール（ビタミンＥ）、酵素処理ルチン等が挙げられる。
前記他の成分は、それぞれ当業者が飲食品、医薬品等の組成物に通常採用する範囲内の量で適宜配合することができる。
Examples of thickening agents include carrageenan, gellan gum, xanthan gum, gum arabic, tamarind gum, guar gum, locust bean gum, karaya gum, agar, gelatin, pectin, soybean polysaccharides, and carboxymethylcellulose (CMC).
Examples of the emulsifier include glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, lecithin, plant sterols, and saponin.
Antioxidants include vitamin C, tocopherol (vitamin E), enzyme-treated rutin, and the like.
The other ingredients can be appropriately blended in amounts within the ranges that are normally used by those skilled in the art in compositions such as foods, beverages, and pharmaceuticals.
本発明の第一の実施形態に係る組成物は、デヒドロジンゲロンのみを、フィラグリン及び／又はインボルクリンの遺伝子発現の増強に関与する活性成分として含んでいてもよい。この場合、本発明の第一の実施形態に係る組成物は、フィラグリン及び／又はインボルクリンの遺伝子発現の増強に関与しない、上記のような他の成分を含んでいてよい。 The composition according to the first embodiment of the present invention may contain only dehydrozingerone as the active ingredient involved in enhancing the gene expression of filaggrin and/or involucrin. In this case, the composition according to the first embodiment of the present invention may contain other ingredients as described above that are not involved in enhancing the gene expression of filaggrin and/or involucrin.
＜線維芽細胞賦活用組成物＞
本発明の第二の実施形態は、デヒドロジンゲロンを有効成分として含有する、線維芽細胞賦活用組成物に関する。
本発明の第二の実施形態に係る組成物の対象は典型的にはヒトであるが、ヒトには限定されず他の非ヒト動物、例えばヒト以外の哺乳類であってもよい。
線維芽細胞の賦活により、皮膚の保湿や、シワ形成、肌荒れ、乾燥肌等の皮膚のトラブルの予防又は改善が達成される。
<Fibroblast stimulating composition>
A second embodiment of the present invention relates to a composition for fibroblast stimulating comprising dehydrozingerone as an active ingredient.
The subject of the composition according to the second embodiment of the present invention is typically a human, but is not limited to a human and may be other non-human animals, for example, mammals other than humans.
By activating fibroblasts, it is possible to achieve moisturization of the skin and prevention or improvement of skin problems such as wrinkle formation, rough skin, and dry skin.
線維芽細胞の賦活とは、線維芽細胞の細胞増殖能が上昇していることを指す。線維芽細胞が賦活されていることは、本発明の第二の実施形態に係る組成物を摂取又は投与した対象から採取した線維芽細胞、或いは、本発明の第二の実施形態に係る組成物の存在下で培養した線維芽細胞をＷＳＴ－１試薬含有培養液中でインキュベートした後に培養液の波長４５０～６３０ｎｍの吸光度を測定し、測定された吸光度が、本発明の第二の実施形態に係る組成物を摂取又は投与しない対象から採取した或いは本発明の第二の実施形態に係る組成物の非存在下で培養した線維芽細胞を用いて同様に測定された吸光度よりも高いことにより確認することができる。 Activation of fibroblasts refers to an increase in the cell proliferation ability of fibroblasts. Activation of fibroblasts can be confirmed by measuring the absorbance of the culture medium at wavelengths of 450 to 630 nm after incubating fibroblasts taken from a subject who has taken or been administered the composition according to the second embodiment of the present invention, or fibroblasts cultured in the presence of the composition according to the second embodiment of the present invention, in a culture medium containing a WST-1 reagent, and finding that the measured absorbance is higher than the absorbance measured in a similar manner using fibroblasts taken from a subject who has not taken or been administered the composition according to the second embodiment of the present invention, or fibroblasts cultured in the absence of the composition according to the second embodiment of the present invention.
本発明の第二の実施形態に係る組成物の対象は、好ましくは、線維芽細胞の賦活を必要とする或いは望む対象である。また、本発明の第二の実施形態に係る組成物は、健常な対象に対しても有効である。 The subject of the composition according to the second embodiment of the present invention is preferably a subject who requires or desires fibroblast activation. The composition according to the second embodiment of the present invention is also effective for healthy subjects.
本発明の第二の実施形態に係る組成物は、医薬品、飲食品、化粧品等の各形態の組成物であってよい。飲食品は、機能性表示食品、特定保健用食品、栄養補給のためのサプリメント等の形態のものも包含する。 The composition according to the second embodiment of the present invention may be in the form of a pharmaceutical, food or drink, cosmetic, etc. Food or drink also includes those in the form of functional food, food for specified health use, nutritional supplement, etc.
本発明の第二の実施形態に係る組成物は、好ましくは、経口又は経鼻により摂取又は投与される組成物であり、より好ましくは、経口により摂取又は投与される組成物である。
本発明の第二の実施形態に係る組成物はまた、皮膚に適用され経皮投与される組成物であってもよい。
The composition according to the second embodiment of the present invention is preferably a composition that is ingested or administered orally or nasally, and more preferably a composition that is ingested or administered orally.
The composition according to the second embodiment of the present invention may also be a composition that is applied to the skin and administered transdermally.
本発明の第二の実施形態に係る組成物はまた、生体外の線維芽細胞と共存させることにより該細胞を賦活するための組成物であってもよい。この場合、本発明の第二の実施形態に係る組成物は、細胞を培養するための培地中に添加されて使用される。
本発明の第二の実施形態に係る組成物は、継続的に摂取、投与又は使用されてもよいし、必要時に摂取、投与又は使用されてもよい。
The composition according to the second embodiment of the present invention may also be a composition for activating ex vivo fibroblasts by coexisting with the cells. In this case, the composition according to the second embodiment of the present invention is added to a medium for culturing the cells.
The composition according to the second embodiment of the present invention may be ingested, administered or used continuously, or may be ingested, administered or used when needed.
本発明の第二の実施形態に係る組成物におけるデヒドロジンゲロンの含有量は特に限定されず、例えば、組成物全量あたり０．１～９５重量％のデヒドロジンゲロンを含むことができ、或いは、１日の使用量あたり１μｇ～１０ｇのデヒドロジンゲロンを含むことができる。 The content of dehydrozingerone in the composition according to the second embodiment of the present invention is not particularly limited, and may be, for example, 0.1 to 95% by weight of dehydrozingerone per total amount of the composition, or 1 μg to 10 g of dehydrozingerone per daily usage amount.
本発明の第二の実施形態に係る組成物の形状は、特に限定されず、例えば、液体状、流動状、ゲル状、半固形状、又は固形状などの何れの形状であってもよい。 The shape of the composition according to the second embodiment of the present invention is not particularly limited, and may be, for example, any of liquid, fluid, gel, semi-solid, or solid forms.
本発明の第二の実施形態に係る組成物は、デヒドロジンゲロンに加えて、少なくとも１種の他の成分を更に含んでいてもよい。本発明の第二の実施形態に係る組成物が含み得る、少なくとも１種の他の成分としては、特に限定されないが、好ましくは、医薬品、飲食品、化粧品等の最終的な形態において許容される成分である。 The composition according to the second embodiment of the present invention may further contain at least one other component in addition to dehydrozingerone. The at least one other component that may be contained in the composition according to the second embodiment of the present invention is not particularly limited, but is preferably an ingredient that is acceptable in the final form of a pharmaceutical product, food or beverage, cosmetic, etc.
このような他の成分としては例えば、甘味料、酸味料、ビタミン類、ミネラル類、増粘剤、乳化剤、酸化防止剤、水等が挙げられる。また、必要により、色素、香料、保存料、防腐剤、防かび剤、更なる生理活性物質等を添加してもよい。これらの成分の具体例は、本発明の第一の実施形態に係る組成物に関して説明したものと同様である。
前記他の成分は、それぞれ当業者が飲食品、医薬品等の組成物に通常採用する範囲内の量で適宜配合することができる。
Examples of such other components include sweeteners, acidulants, vitamins, minerals, thickeners, emulsifiers, antioxidants, water, etc. Furthermore, if necessary, colorants, flavors, preservatives, antiseptics, fungicides, further physiologically active substances, etc. Specific examples of these components are the same as those described with respect to the composition according to the first embodiment of the present invention.
The other ingredients can be appropriately blended in amounts within the ranges that are normally used by those skilled in the art in compositions such as foods, beverages, and pharmaceuticals.
本発明の第二の実施形態に係る組成物は、デヒドロジンゲロンのみを、線維芽細胞の賦活に関与する活性成分として含んでいてもよい。この場合、本発明の第二の実施形態に係る組成物は、線維芽細胞の賦活に関与しない、上記のような他の成分を含んでいてよい。 The composition according to the second embodiment of the present invention may contain only dehydrozingerone as an active ingredient involved in fibroblast activation. In this case, the composition according to the second embodiment of the present invention may contain other ingredients as described above that are not involved in fibroblast activation.
＜実施例１＞
ヒト由来表皮角化細胞株（ＮＨＥＫ）を、１ウェルあたり１×１０５細胞になるようにＨｕＭｅｄｉａ－ＫＧ２培地に懸濁し、懸濁液を２４ウェルプレートに播種し、３７℃、５％ＣＯ２条件下で培養した。
培養開始から２４時間後に、デヒドロジンゲロン（ＤＨＺ）を終濃度で１０μＭ、５０μＭ又は１００μＭ含有する培地（Ｈｙｄｒｏｃｏｒｔｉｓｏｎｅを含まない）に交換し、更に７２時間培養した。
対照としてデヒドロジンゲロンを含まない前記培地を用いた以外は同一の方法で表皮角化細胞株の培養を行った。
デヒドロジンゲロンは、市販の試薬を東京化成工業株式会社から入手して使用した。
Example 1
A human epidermal keratinocyte cell line (NHEK) was suspended in HuMedia-KG2 medium to give a density of 1 x 105 cells per well, and the suspension was seeded onto a 24-well plate and cultured at 37°C under 5% CO2 conditions.
24 hours after the start of the culture, the medium was replaced with a medium (not containing hydrocortisone) containing dehydrozingerone (DHZ) at a final concentration of 10 μM, 50 μM or 100 μM, and the culture was continued for an additional 72 hours.
As a control, an epidermal keratinocyte cell line was cultured in the same manner, except that the above medium containing no dehydrozingerone was used.
Dehydrozingerone was used as a commercially available reagent obtained from Tokyo Chemical Industry Co., Ltd.
培養後の細胞をＰＢＳで洗浄し、細胞を回収して、細胞からＲＮＡを抽出した。細胞の回収およびＲＮＡの抽出にはＲＮｅａｓｙ Ｍｉｎｉ Ｋｉｔ（ＱＩＡＧＥＮ）を用い、付属の手順に従って行った。 After culturing, the cells were washed with PBS, harvested, and RNA was extracted from the cells. Cell harvesting and RNA extraction were performed using RNeasy Mini Kit (QIAGEN) according to the attached procedure.
得られたＲＮＡを使用し、リアルタイムＰＣＲによってフィラグリン（ＦＬＧ）及びインボルクリン（ＩＮＶ）、並びに、内部標準としてリボソームタンパク質Ｓ１８（ＲＰＳ１８）のｍＲＮＡ発現量を測定した。Ｏｎｅ Ｓｔｅｐ ＴＢ Ｇｒｅｅｎ ＰｒｉｍｅＳｃｒｉｐｔ ＲＴ－ＰＣＲ Ｋｉｔ ＩＩ（タカラバイオ）を用い、付属のプロトコルに従って行った。プライマー配列は次表の通り。 The obtained RNA was used to measure the mRNA expression levels of filaggrin (FLG) and involucrin (INV), as well as ribosomal protein S18 (RPS18) as an internal standard by real-time PCR. The One Step TB Green PrimeScript RT-PCR Kit II (Takara Bio) was used, and the procedure was carried out according to the attached protocol. The primer sequences are as shown in the following table.
フィラグリン（ＦＬＧ）及びインボルクリン（ＩＮＶ）のｍＲＮＡ発現量を、ＲＰＳ１８のｍＲＮＡ発現量に対する相対値として算出した。更に、各デヒドロジンゲロン濃度条件でのフィラグリン（ＦＬＧ）及びインボルクリン（ＩＮＶ）の算出したｍＲＮＡ発現量を、対照条件での各タンパク質の算出したｍＲＮＡ発現量に対する相対値として表した。 The mRNA expression levels of filaggrin (FLG) and involucrin (INV) were calculated as relative values to the mRNA expression level of RPS18. Furthermore, the calculated mRNA expression levels of filaggrin (FLG) and involucrin (INV) under each dehydrozingerone concentration condition were expressed as relative values to the calculated mRNA expression levels of each protein under control conditions.
各条件についてｎ＝３で測定を行い、平均値及び標準偏差を求めた。また、Ｄｕｎｎｅｔｔの検定による有意差検定を行った。フィラグリン（ＦＬＧ）のｍＲＮＡ発現量を図１に示す。インボルクリン（ＩＮＶ）のｍＲＮＡ発現量を図２に示す。図１、図２において、対照（Ｃｔｒ）に対する有意差を、＊＊：ｐ＜０．０１で示す。
デヒドロジンゲロンの濃度に依存して、保湿因子であるフィラグリン及びインボルクリンのｍＲＮＡ発現量が増加した。
Measurements were performed for each condition (n=3), and the average value and standard deviation were calculated. A significant difference test was also performed using Dunnett's test. The expression level of filaggrin (FLG) mRNA is shown in Figure 1. The expression level of involucrin (INV) mRNA is shown in Figure 2. In Figures 1 and 2, significant differences compared to the control (Ctr) are indicated with **: p<0.01.
The mRNA expression levels of moisturizing factors filaggrin and involucrin increased depending on the concentration of dehydrozingerone.
＜実施例２＞
マウス由来線維芽細胞株（３Ｔ３－Ａ３１）を、１ウェルあたり１×１０４細胞になるようにＤＭＥＭ培地（２％ＦＢＳ、ｌｏｗ ｇｌｕｃｏｓｅ）に懸濁し、懸濁液を９６ウェルプレートに播種し、３７℃、５％ＣＯ２条件下で培養した。
Example 2
A mouse-derived fibroblast cell line (3T3-A31) was suspended in DMEM medium (2% FBS, low glucose) to give 1 x 104 cells per well, and the suspension was seeded onto a 96-well plate and cultured at 37°C under 5% CO2 conditions.
培養開始から２４時間後に、デヒドロジンゲロン（ＤＨＺ）を終濃度で０．５μＭ、１μＭ、５μＭ、１０μＭ、５０μＭ又は１００μＭとなるように添加し、更に２４時間、４８時間又は７２時間培養した。
対照としてデヒドロジンゲロンを含まない前記培地を用いた以外は同一の方法で線維芽細胞株の培養を行った。
デヒドロジンゲロンは、市販の試薬を東京化成工業株式会社から入手して使用した。
24 hours after the start of the culture, dehydrozingerone (DHZ) was added to a final concentration of 0.5 μM, 1 μM, 5 μM, 10 μM, 50 μM or 100 μM, and the culture was continued for a further 24, 48 or 72 hours.
As a control, a fibroblast cell line was cultured in the same manner, except that the above medium containing no dehydrozingerone was used.
Dehydrozingerone was used as a commercially available reagent obtained from Tokyo Chemical Industry Co., Ltd.
２４時間、４８時間又は７２時間培養後に９６ウェルプレートにＷＳＴ－１試薬を加えて２時間インキュベートした後、波長４５０～６３０ｎｍの吸光度（細胞の代謝活性）をプレートリーダーで測定した。ここでいう細胞の代謝活性とは、細胞の増殖活動及び、過度の活性化を含む生命維持活動を意味する。
各条件についてｎ＝３で測定を行い、平均値及び標準偏差を求めた。また、Ｄｕｎｎｅｔｔの検定による有意差検定を行った。
After 24, 48 or 72 hours of culture, WST-1 reagent was added to the 96-well plate and incubated for 2 hours, after which the absorbance at wavelengths of 450 to 630 nm (metabolic activity of cells) was measured using a plate reader. The metabolic activity of cells here refers to proliferation activity of cells and life-sustaining activity including excessive activation.
Measurements were performed for each condition (n=3), and the average value and standard deviation were calculated. In addition, a significant difference test was performed using Dunnett's test.
デヒドロジンゲロン含有培地中で２４時間、４８時間及び７２時間培養した後の吸光度の測定結果をそれぞれ図３、図４及び図５に示す。図３～５において、対照（Ｃｔｒ）に対する有意差を、＊：ｐ＜０．０５、＊＊：ｐ＜０．０１で示す。 The results of measuring the absorbance after culturing in dehydrozingerone-containing medium for 24, 48, and 72 hours are shown in Figures 3, 4, and 5, respectively. In Figures 3 to 5, significant differences from the control (Ctr) are indicated with *: p<0.05 and **: p<0.01.
図３～５に示す結果は、５μＭ、１０μＭ、５０μＭ又は１００μＭのデヒドロジンゲロン（ＤＨＺ）の存在下で線維芽細胞株の代謝活性が増大することを示唆する。 The results shown in Figures 3 to 5 suggest that the metabolic activity of fibroblast cell lines increases in the presence of 5 μM, 10 μM, 50 μM, or 100 μM dehydrozingerone (DHZ).
線維芽細胞は、ヒアルロン酸、コラーゲン等の保湿成分を産生する。デヒドロジンゲロンは、線維芽細胞を活性化し、保湿成分を増加させることが示唆された。 Fibroblasts produce moisturizing components such as hyaluronic acid and collagen. It has been suggested that dehydrozingerone activates fibroblasts and increases moisturizing components.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020118002A JP7505680B2 (en) | 2020-07-08 | 2020-07-08 | Composition for enhancing filaggrin and/or involucrin gene expression, and composition for stimulating fibroblasts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020118002A JP7505680B2 (en) | 2020-07-08 | 2020-07-08 | Composition for enhancing filaggrin and/or involucrin gene expression, and composition for stimulating fibroblasts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022022849A JP2022022849A (en) | 2022-02-07 |
| JP7505680B2 true JP7505680B2 (en) | 2024-06-25 |
Family
ID=80224999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020118002A Active JP7505680B2 (en) | 2020-07-08 | 2020-07-08 | Composition for enhancing filaggrin and/or involucrin gene expression, and composition for stimulating fibroblasts |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7505680B2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004075632A (en) | 2002-08-21 | 2004-03-11 | Noevir Co Ltd | Dermatofibroblast activator |
| JP2006347976A (en) | 2005-06-17 | 2006-12-28 | Noevir Co Ltd | Dermal fibroblast activator |
| JP2009539917A (en) | 2006-06-12 | 2009-11-19 | シャネル パルファン ボーテ | Cosmetic use of cashmunalin, arylbutenoids and / or plant extracts containing them |
| JP2014509631A (en) | 2011-04-01 | 2014-04-21 | ロレアル | Use of zingerone or its derivatives to reduce or delay the signs of skin aging |
-
2020
- 2020-07-08 JP JP2020118002A patent/JP7505680B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004075632A (en) | 2002-08-21 | 2004-03-11 | Noevir Co Ltd | Dermatofibroblast activator |
| JP2006347976A (en) | 2005-06-17 | 2006-12-28 | Noevir Co Ltd | Dermal fibroblast activator |
| JP2009539917A (en) | 2006-06-12 | 2009-11-19 | シャネル パルファン ボーテ | Cosmetic use of cashmunalin, arylbutenoids and / or plant extracts containing them |
| JP2014509631A (en) | 2011-04-01 | 2014-04-21 | ロレアル | Use of zingerone or its derivatives to reduce or delay the signs of skin aging |
Non-Patent Citations (6)
| Title |
|---|
| Bioorganic & Medicinal Chemistry，2016年，24，pp.501-520 |
| J. Cell. Mol. Med.，2015年，19(3)，pp.620-629 |
| Mol Cell Biochem，2011年，355，pp.249-256 |
| The Journal of Biological Chemistry，2003年，278(36)，pp.34277-34285 |
| The Journal of Investigative Dermatology，2004年，123，pp.564-573 |
| The Journal of Investigative Dermatology，2014年，134，pp.2693-2702 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022022849A (en) | 2022-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI500428B (en) | Sugar-free pineapple extract, method for producing the extract, and application of the extract | |
| CN103989589A (en) | Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care | |
| KR102488588B1 (en) | Compositions for Skin-lightening Using Using Solubilized Mastic Gum | |
| JP2011088845A (en) | Involucrin expression inhibitor | |
| KR101295368B1 (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
| JP5645344B2 (en) | External preparation composition | |
| KR20190072445A (en) | Vinegar with enhanced skin whitening effect using Aster scaber and Ficus carica and production method thereof | |
| KR101721022B1 (en) | Composition for comprising adipic acid for improving skin wrinkle or enhancing skin elasticity | |
| JP7505680B2 (en) | Composition for enhancing filaggrin and/or involucrin gene expression, and composition for stimulating fibroblasts | |
| CN106852725A (en) | Composition for improving skin | |
| JP6677446B2 (en) | Cosmetics | |
| WO2020255989A1 (en) | Novel compound derived from watermelon, and composition using same | |
| RU2548794C2 (en) | Elastase inhibitor | |
| EP3162375B1 (en) | Whitening composition comprising scutellaria alpina extract | |
| KR101528449B1 (en) | A composition for improving skin conditions containing tetrandrine | |
| JP2017206468A (en) | Lysosome activity promotor | |
| JP6039465B2 (en) | Oral pharmaceutical composition, dry mouth improving agent, dry mouth preventive agent, and aquaporin production promoter | |
| KR102054194B1 (en) | Anti-obesity composition comprising Suaeda japonica extract as effective component | |
| JP2009161526A (en) | Treating agent | |
| JP2017081874A (en) | Skin moisturizer for oral ingestion or administration | |
| CN106389141A (en) | Skin improving composition | |
| JP2013014627A (en) | Heparin-binding epidermal growth factor-like growth factor (hb-egf) production promoter | |
| KR102200013B1 (en) | Composition comprising artemisia umbelliformis extract | |
| KR102626704B1 (en) | Composition for promoting hair growth comprising rose petal extract as an active ingredient | |
| KR102229943B1 (en) | Composition for Skin-lightening and Improving Wrinkle Using an Extract of Maerua edulis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A625 | Written request for application examination (by other person) |
Free format text: JAPANESE INTERMEDIATE CODE: A625 Effective date: 20230425 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240410 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240603 |